We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-26.27%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$2.23B
AUM Growth
-$1.32B
Cap. Flow
-$302M
Cap. Flow %
-13.54%
Top 10 Hldgs %
55.24%
Holding
55
New
2
Increased
1
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
TWST icon
Twist Bioscience
TWST
+$11.6M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$10.5M
3
TSVT
2seventy bio
TSVT
+$10.4M

Top Sells

Rank Stock Value
1
CDXS icon
Codexis
CDXS
+$83.5M
2
EXAS
Exact Sciences
EXAS
+$51.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$42.1M
4
ALLO icon
Allogene Therapeutics
ALLO
+$39.5M
5
ALEC icon
Alector
ALEC
+$34.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MASS icon
51
908 Devices
MASS
$345M
– –
-406,502
Closed -$10.5M
SANA icon
52
Sana Biotechnology
SANA
$885M
– –
-60,000
Closed -$929K
STOK icon
53
Stoke Therapeutics
STOK
$1.84B
– –
-120,000
Closed -$2.88M
ME
54
DELISTED
23andMe Holding Co
ME
– –
-92,073
Closed -$12.3M
CELL
55
DELISTED
PhenomeX Inc. Common Stock
CELL
– –
-200,000
Closed -$3.64M
1 2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Casdin Capital held 55 positions worth $2.23B, down 37% from $3.55B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Casdin Capital withdrew a net $302M in Q1 2022, closing 8 positions and reducing 7 holdings. Its most notable exit was Allogene Therapeutics, an estimated $39.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier.

Against the trend, Casdin Capital opened a new position in Mirati Therapeutics, Inc. Common Stock worth $8.43M.

  • Casdin Capital's largest Q1 2022 buy was Mirati Therapeutics, Inc. Common Stock: 102,500 shares worth $8.43M.
  • Casdin Capital added most to Twist Bioscience in Q1 2022, an estimated $11.6M increase.
  • Casdin Capital's biggest Q1 2022 reduction was Codexis, cutting an estimated $83.5M.
  • Casdin Capital fully exited Allogene Therapeutics in Q1 2022, selling an estimated $39.5M.
  • Casdin Capital's ten largest holdings make up 55% of its $2.23B portfolio in Q1 2022.
  • Casdin Capital opened 2 new positions and closed 8 in Q1 2022.
  • Casdin Capital's portfolio value fell 37% quarter-over-quarter to $2.23B.

Based on Casdin Capital's 13F filing for Q1 2022, filed 16 May 2022.